BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  company  Otsuka  Pharmaceutical  Europe  Ltd  submitted  on  5  December  2001  an  application  for 
Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) 
for  Abilify,  through  the  centralised  procedure.  After  agreement  by  the  CPMP  on  28  June  2001,  this 
medicinal product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 
of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur: 
Prof C. Sampaio 
Co-Rapporteur: 
Pharm. M. Avgerinos 
Scientific Advice: 
The applicant did not seek scientific advice at the CPMP. 
Licensing status: 
Abilify has been given a Marketing Authorisation in Mexico on 17 July 2002, in Brazil on 11 April 
2003, in  the  USA  on 15  November  2002, in Puerto  Rico  on 25  November  2002, in  Australia  on  21 
May 2003 and in Peru on 20 May 2003. 
A new application was filed in the following countries: Switzerland, Turkey, Japan and Malaysia. 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 24 December 2001. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP  members  on  13  March 
2002 . The Co-Rapporteur's first Assessment Report was circulated to all CPMP members on 4 
March 2002 
During  the  meeting  on  23-25  April  2002,  the  CPMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on  25 April 2002  
GCP inspections were carried out at two sites, one in Bulgaria on 19-21 June 2002 and the other 
in Estonia on 26-28 June 2002. (Study 31-98-304-01). 
The  applicant  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on  3 
September 2002. 
The Rapporteur’s circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CPMP members on 28 October 2002.  
During  the  CPMP  meeting  on  19-21  November  2002,  the  CPMP  agreed  on  a  List  of 
Outstanding Issues to be addressed in writing and/or in an oral explanation by the applicant. 
During the CPMP meeting on 18-20 February 2003, outstanding issues were addressed by the 
applicant during an oral explanation before the CPMP. 
Follow up GCP inspections were carried out in Poland on 4-6 March 2003, in France on 19-21 
March 2003, and at three sites in Russia on 28 and 31 March 2003, 1-2 April 2003 and 3-4 April 
2003. (Study 31-98-304-01). 
The applicant submitted the responses to the CPMP List of Outstanding Issues on 16 June 2003. 
The  Rapporteur  circulated  the  Assessment  Report  on  the  applicant’s  responses  to  the  List  of 
Outstanding Issues to all CPMP members on 17 July 2003.  
During the CPMP meeting on 22-24 July 2003, the CPMP agreed on a 2nd List of Outstanding 
Issues to be addressed in writing and/or in an oral explanation by the applicant. 
1/2                                                                          EMEA 2005 
 
 
 
• 
• 
• 
• 
• 
• 
The  applicant  submitted  the  responses  to  the  2nd  CPMP  List  of  Outstanding  Issues  on  27 
October 2003. 
The Rapporteur circulated the Assessment Report on the applicant’s responses to the 2nd List of 
Outstanding Issues to all CPMP members on 12 November 2003.  
During the CPMP meeting on 18-20 November 2003, outstanding issues were addressed by the 
applicant during an oral explanation before the CPMP. 
A GMP inspection for the clinical trial batch records (Study 31-98-304-01) was carried out at 
the CRO on 7-9 January 2004.  
During  the  meeting  on  24-26  February  2004,  the  CPMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting a Marketing Authorisation to Abilify on 26 February 2004. The applicant provided the 
letter of undertaking on the follow-up measures to be fulfilled post-authorisation on 24 February 
2004. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 4 June 2004. 
2/2                                                                          EMEA 2005 
 
 
